Special Issue

A New Generation of Metal Anticancer Drugs

Message from the Guest Editor

This Special Issue will explore advancements in the design and development of new metal-based anticancer drugs, focusing on optimizing therapeutic potential while minimizing toxicity. Metal-containing compounds, such as platinum-based drugs (e.g., cisplatin) and emerging metal complexes, have shown promise in cancer treatment, but their chemoresistance and side effects often pose challenges. In designing novel metallodrugs, addressing issues related to bioavailability, stability, resistance, and side effects is crucial.

This Special Issue will also explore novel drug delivery systems, including nanoparticles, liposomes, and conjugated formulations, which enhance solubility, targeting specificity, and controlled release of metal-based agents. It will address the pharmacokinetics and pharmacodynamics of metal-based drugs, focusing on improving tissue distribution and tumor accumulation.

Researchers and pharmaceutical scientists are invited to contribute insights into formulation design, characterization, and clinical translation of metal-based anticancer therapies, aiming to provide safer and more effective treatment options for cancer patients.

Guest Editor

Dr. Ignacio E. León

CEQUINOR (UNLP, CCT-CONICET La Plata, Asociado a CIC), Departamento de Química, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata 1900, Argentina

Deadline for manuscript submissions

closed (30 November 2025)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/223646

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

